A Di Bartolomeo, J George - Metabolic Steatotic Liver Disease, 2024 - Elsevier
Fatty liver disease is an important cause of chronic liver disease affecting one quarter of the world's population. There is debate regarding the most appropriate name and definition for …
V Ajmera, R Loomba - Journal of hepatology, 2023 - journal-of-hepatology.eu
We thank Binet et al. for their comments regarding our recently published manuscript characterizing the prevalence of NAFLD, advanced fibrosis and cirrhosis in a prospectively …
Background: This study aimed to explore the effectiveness of endoscopic ultrasound elastography (EUS-EG) in evaluating liver fibrosis. Methods: The present study involved 11 …
M Basheer, M Naffaa, N Assy - Clinical and Molecular Hepatology, 2023 - e-cmh.org
The search for reliable and non-invasive biomarkers of liver fibrosis has been a focus of intense medical research, with the aim of improving patient outcomes through early …
EL Jensen, M Thiele - Alcohol and Alcohol-related Diseases, 2023 - Springer
Alcohol-related liver disease is present in 4–9% of the population and occurs after years of excessive drinking. Liver cirrhosis develops after decades of heavy drinking, but the …
F Tavaglione, R Loomba - Journal of Clinical and Experimental …, 2024 - jcehepatology.com
Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease globally. 1, 2 It is commonly associated with obesity, dyslipidemia, insulin resistance …
S Sankararaman, AJ Freeman - Authorea Preprints, 2023 - essopenarchive.org
Cystic fibrosis-related hepatobiliary involvement (CFHBI) is a term used to describe a spectrum of hepatobiliary involvement ranging from benign elevation of transaminase levels …
Nonalcoholic fatty liver disease, hereafter referred to simply as fatty liver disease, is the most widespread liver disease, with an estimated prevalence of 38% of the global adult …